Iovance Biotherapeutics, a biotechnology company developing cancer immunotherapies, and MaSTherCell S.A., a cell therapy CDMO, have entered into a new three-year manufacturing services agreement under which MaSTherCell will manufacture TIL for Iovance’s late-stage clinical trials at its commercial-ready cGMP manufacturing suites. 
 
“We are pleased to be expanding our clinical and manufacturing capacity in Europe through this new collaboration with MaSTherCell. We have been dosing patients with lifileucel in Europe for the treatment of metastatic melanoma and LN-145 for the treatment of cervical cancers. As part of our global development plan for our TIL product, we are initiating the IOV-COM-202 trial in Europe as well and have received approval from Medicines and Healthcare products Regulatory Agency (MHRA). This newly established relationship with MaSTherCell will add additional commercial-ready capacity to support our ongoing and upcoming trials,” said Dr. Maria Fardis, PhD, MBA, president and chief executive officer of Iovance Biotherapeutics.
 
“We are glad that Iovance called on our expertise to accelerate the development of their TIL products. By addressing the unmet needs for solid tumor treatment, the outcome of this project could represent an enormous hope for a considerable number of patients,” said Dr. Denis Bedoret, general manager of MaSTherCell. “MaSTherCell is really pleased to welcome Iovance in its new commercial plant for advanced cell therapy manufacturing.”